BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:30 AM
 | 
Mar 21, 2019
 |  BC Extra  |  Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

Editor's Note: This article was updated on Mar 21, 2019 at 5:48 PM PDT

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more pressure on Biogen to add to its Phase III pipeline.

The companies made the announcement Thursday based on an interim futility analysis and recommendation from an IDMC of its Phase III ENGAGE and EMERGE trials. The partners will discontinue the studies, as well as two other studies of the candidate.

Biogen Inc. (NASDAQ:BIIB) shares were battered on Thursday, sinking $93.71 (29%) to $226.88....

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >